Novo Nordisk: Oddo BHF still a buyer
(CercleFinance.com) - Oddo BHF maintains its Outperform rating on Novo Nordisk shares, with a target price of 1,210 DKK.
The analyst welcomes Novo's announcement of the results of the Oasais program to evaluate semaglutide, saying that this trial is proving to be a success, thereby confirming Novo's leadership in the indication.
These results reinforce Novo Nordisk's expertise and scope in the control of obesity. They should also reassure investors regarding Novo Nordisk's ability to meet both demand and position itself as a pioneer in a substantial market, the analyst adds.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The analyst welcomes Novo's announcement of the results of the Oasais program to evaluate semaglutide, saying that this trial is proving to be a success, thereby confirming Novo's leadership in the indication.
These results reinforce Novo Nordisk's expertise and scope in the control of obesity. They should also reassure investors regarding Novo Nordisk's ability to meet both demand and position itself as a pioneer in a substantial market, the analyst adds.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.